26 October 2016. Prous Institute has been invited to speak at the Chem-Bio Informatics Society (CBI) Annual Meeting “Future outlook of in silico drug discovery: Collaboration of simulation, structural biology and big data for innovative drug discovery” which takes place in Tokyo, Oct. 24-27, 2016.
During the Focused Session “Computational toxicology related topics” (Weds Oct. 26, 16:00-17:30), Josep Prous, Jr., Ph.D., Vice President Research and Development at Prous Institute for Biomedical Research, will present “The Usefulness of In Silico Technologies to Minimize Off-Target Safety Pharmacology Events”.
In his presentation, Dr Prous, Jr. will introduce specific examples in which comprehensive use of the in silico approach can support the design of an adequate off-target safety assessment strategy for novel investigational drugs.
A lot of interest has been placed recently in the field of off-target pharmacology, and major pharmaceutical companies have tried to build a consensus and determine the targets which should be screened to avoid unwanted and costly surprises during the preclinical toxicology and clinical development stages. Additionally, regulatory policies are evolving from the obligation to submit a limited number of safety endpoints to a request for a wider collection of secondary pharmacology data.
Unfortunately, an exhaustive and comprehensive study of all the potential off-target interactions for investigational compounds can be tremendously costly considering the experimental screening of thousands of drug candidates.
In this regard, the use of knowledge management and predictive technologies can be of great benefit for optimizing the candidate selection process.
Taking this scenario into consideration, Prous Institute for Biomedical Research has developed an innovative in silico solution, Symmetry, to accelerate drug discovery and minimize potential liabilities.
The platform helps to de-risk and prioritize projects and assays and speed up drug discovery and development, reducing time, costs and attrition rates. Symmetry applies advanced machine learning techniques to a variety of structural features and physicochemical properties of small molecules to provide quality predictions of biological effects.
Symmetry’s Global Mechanism of Action model predicts on- and off-target activities of small molecules and is based on a large training set of over 1 million compounds and over 1.5 million Structure-Activity Relationships (SAR).
For further information or to schedule a meeting during the conference, please contact email@example.com.
About the Chem-Bio Informatics Society
The Chem-BioInformatics (CBI) Society is a Japanese non-profit organization that aims to provide a platform for promoting cutting-edge interdisciplinary areas related to chemistry, biology, and informatics. The CBI Society has interest in molecular recognition and molecular modeling, in silico drug discovery, bioinformatics and its applications in medicine, information and computing approaches for drug design and ADMET studies, and emerging new technologies.
About Prous Institute for Biomedical Research
Prous Institute for Biomedical Research is a privately-held research organization. It was founded as a spin-off of Prous Science, the leading scientific information provider (producer of Drugs of the Future, Drug Data Report and the Integrity drug discovery and development portal, amongst others) acquired by Thomson Reuters in 2007. Prous Institute built on over 50 years of experience creating and managing biomedical knowledge to develop Symmetry, an innovative predictive analytics platform that enables the generation of new research hypotheses and predicts the therapeutic and safety profile of small molecules.